HLB's liver cancer therapy proves effective across all age groups in new study
HLB Group's liver cancer combination therapy showed consistent treatment benefits regardless of patient age, including in patients under 40, according to a new subgroup analysis to be presented this week at an international cancer conference. Elevar Therapeutics, HLB's U.S. subsidiary, will present an age-based post-hoc analysis of its global Phase 3 CARES-310 trial in a poster session at the…
The HLB Group's liver cancer therapy, a combination of rivoceranib and camrelizumab, demonstrated consistent treatment benefits across all age groups in a new study. Presented at an upcoming international conference, the research from Elevar Therapeutics' U.S. subsidiary highlights the effectiveness of the drug combination in patients under 40.
Median overall survival for younger patients reached 21.5 months, compared to 15.2 months for those on the standard treatment sorafenib. Progression-free survival, the time before the cancer worsens, was also significantly higher in the younger group at 5.5 months versus 2.7 months. Even for patients over 50, the therapy showed promising results with an overall survival rate of 23.9 months, compared to 1.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
